Anticoagulation Forum/LinkedIn
Jun 22, 2026, 15:08
Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
Anticoagulation Forum shared a post on LinkedIn:
“Recording now available!
We are grateful to our expert faculty for sharing their time, and their thoughtful discussions, and insights during our recent webinar:
Apixaban vs. Rivaroxaban in Acute VTE: Uncoiling COBRRA and Its Clinical Implications
This session explored the clinical questions behind the COBRRA trial, including retrospective evidence, potential pharmacologic explanations, study design, key findings, and practical implications for frontline VTE care.
Faculty:
- Arthur Allen, PharmD
- Lana Castellucci, MD
- Steven Deitelzweig, MD
- Jori May, MD
If you missed the live webinar, want to revisit the discussion, or know a colleague who may benefit, the recording is available to watch for free on our Archived Webinars page.
-
Sep 25, 2026, 13:32Gevorg Yaghjyan: Low Drug Levels, Higher Cardiovascular Risk in Lupus
-
Sep 25, 2026, 12:53Bastu Odoka: What Happened to Blood Donation?
-
Sep 25, 2026, 12:43Thomas Dayspring: Reshaping the Biology of Atherosclerotic Plaques with New Therapies
-
Sep 25, 2026, 12:14Garima Sharma: Community Clinical Linkages for Better Postpartum Cardiovascular Care
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD